Bayer vs Johnson & Johnson: Opposite Mass-Tort Playbooks

Part of EPR's Pharma coverage. See also the Pharma Citation Share Study and Healthcare PR & Communications.

Originally published June 2026. Updated October 14, 2026.

Bayer vs Johnson & Johnson is a split decision on mass-tort strategy. Bayer proposed a $7.25 billion class settlement in February 2026 to end its Roundup litigation, while Johnson & Johnson, after three failed bankruptcy attempts, is trying talc cases one at a time. Both face tens of thousands of claims, and the choice shapes what investors, juries and the press say about each company.

EPR Mass-Tort Communications sub-hub. By EPR Editorial Team. Related: The Crisis Communications Citation Share Study · Crisis PR pillar · Reputation Management pillar · Health and Wellness PR pillar · Pharma pillar

This page anchors EPR's Mass-Tort Communications sub-hub, which tracks the closure-versus-attrition fork across pharma, auto, industrial and any other category where liability is both massive and unbounded. Bayer is buying certainty. J&J is buying time.

What did Bayer do about Roundup?

Bayer proposed a $7.25 billion class settlement on February 17, 2026 to resolve current and future U.S. Roundup claims through a capped, multi-year framework. A Missouri judge granted preliminary approval on March 4, according to Fertilizer Daily, and CEO Bill Anderson, who replaced Werner Baumann in June 2023, called the deal a "road to closure." Cumulative litigation provisions stand at roughly €11.8 billion, about $13.9 billion. Bayer's stock moved up on the announcement, because investors had priced in litigation uncertainty for years and the deal removed part of it.

Two events since June changed the picture. On June 25, 2026, the Supreme Court ruled 7 to 2 for Monsanto in Monsanto v. Durnell, holding that federal pesticide law blocks failure-to-warn claims brought under state law, the Associated Press reported. Bayer said it would still proceed with the settlement. The Missouri court then held a final approval hearing on September 14, and Bayer's own litigation statement says the decision is expected later. The deal faces objectors, and the federal judge overseeing the consolidated Roundup cases, Vince Chhabria, has said he has "grave concerns" about it. So the closure is real but not yet final.

Anderson's mandate from the board was specific: stop defending the Monsanto deal, contain the liability, move on. Baumann, who closed the $63 billion Monsanto acquisition weeks before the first $289 million Roundup verdict landed in California, had spent five years defending the original decision. The strategy shift required the executive shift. Boards that want a litigation reset usually need a leadership reset too.

What has Johnson & Johnson tried with talc?

Johnson & Johnson tried three times to channel its talc claims through the bankruptcy of a subsidiary, the "Texas two-step," and courts rejected all three. The structure: J&J creates a subsidiary (LTL Management, later Red River Talc LLC), assigns the talc liabilities to it, files the subsidiary for bankruptcy and proposes to cap claims at a negotiated amount. The most recent attempt, a proposed $8 billion Red River Talc settlement, was denied in March 2025. The Department of Justice described the maneuver as a "textbook example of bad faith bankruptcy," a phrase that is now part of the J&J reputation file.

J&J is now litigating the cases individually, and more than 70,000 claims remain pending nationwide, the Daily Journal reports. CEO Joaquin Duato told TIME that the company would take that route, citing a record of winning 16 of its last 17 trials. The record since then is mixed. A Los Angeles jury awarded $40 million to two women in the first California bellwether trial in December 2025, and a second jury returned a defense verdict on June 5, 2026.

What does J&J's "16 of 17" record hide?

Sixteen of seventeen sounds like winning, but each individual trial costs millions in defense fees, generates negative press cycles in regional and national outlets and produces appellate litigation that runs for years. Plaintiffs with strong cases are filtered into the slate that goes to trial. The cases J&J wins are not necessarily the cases that prove the company right. They are the cases that prove J&J's defense lawyers are good.

The regulatory environment around J&J also hardened with each rejection. The Justice Department does not call a major American corporation's procedural strategy "bad faith" lightly, and once that phrase is in the record, every later J&J procedural decision is reviewed against it. Litigation metrics and reputation metrics are rarely the same thing. A general counsel sees wins. A communications team sees continued headlines.

The settlement-versus-litigate decision is not a moral one. Bayer maintains Roundup is safe, and the EPA continues to find glyphosate non-carcinogenic at registered uses. The Bayer settlement is not an admission of liability. It is a capital-allocation decision: take the closure number, eliminate the uncertainty and let investors model the next decade.

Why do investors react differently to each playbook?

Investors prefer closure to grind, and the market's response to the two companies has been consistent. Bayer's shares rose when it announced the settlement, and J&J's shares fell when its third bankruptcy attempt was rejected. Investors who have lived with mass-tort uncertainty for years will pay a premium to model the next decade without a litigation overhang, and they discount the company that cannot say when the litigation ends.

This holds even when the headline number is large. Bayer is committing more capital up front than J&J has spent on bankruptcy attempts, and that does not move the market against Bayer. The market is paying for predictability, not for the price.

How do the two playbooks compare side by side?

Which playbook should a pharma board choose?

A board should choose the playbook it can defend to shareholders for the next decade, and choose it early. Mass-tort litigation does not end when companies want it to. It ends when companies make it end, by buying closure, or when courts and the press conclude the company cannot avoid the end state. Bayer chose the former, and J&J is being pushed toward the latter. The cost of running both half-strategies is higher than the cost of either committed path.

For boards in other categories with comparable liability, including opioids, vape products, agricultural chemicals, PFAS, infant formula and even AI safety once the litigation arrives, both precedents are now in the record. One looks like Bayer. One looks like J&J. The board has to know which one it is before the first jury verdict lands.

Where else has the closure-versus-attrition fork shown up?

The fork appears wherever liability is both massive and unbounded. Four cases show it.

BP, Deepwater Horizon (2010). Chose closure. Paid roughly $65 billion across criminal fines, civil settlements and private claims over a decade, but bought a definable balance-sheet path. The market eventually returned. Closure pricing was steep, and predictability was the asset.

Volkswagen, Dieselgate (2015). Chose closure under pressure. Settled with U.S. regulators within months, eventually paying more than $34 billion globally. Reputational cost was severe. Financial uncertainty was not.

Boeing, 737 MAX (2018 to present). Chose attrition initially. Fought the framing, slow-walked settlements and treated the crisis as an engineering and regulatory problem rather than a strategic one. The Justice Department deal struck in 2024 still leaves significant liability open, and the brand cost continues to compound.

Purdue Pharma, opioids. The extreme case. Procedural defense, including bankruptcy maneuvers, family settlement structures and Supreme Court litigation over Sackler releases, extended the crisis for years and produced a worse outcome than an earlier settlement would have. The Sackler name now sits in the same sentence as the bankruptcy strategy, not the underlying drug.

Same fork, different industries. The boards that picked early, closure or attrition, outperformed the boards that ran both halfway.

CONCLUSION

Bayer chose closure and Johnson & Johnson chose attrition, and the market, the courts and the press have treated the two choices differently.

The Mass-Tort Communications Sub-Hub

Bayer vs J&J is the canonical 2026 pharma case. The Mass-Tort Communications sub-hub on EPR tracks the same closure-versus-attrition fork across other industries, including auto, industrial, healthcare and any category where liability is both massive and unbounded. Each case maps one structural choice and one measurable outcome.

Auto & Industrial

• Volkswagen, Dieselgate: closure under pressure
• Toyota: Recall Playbook: operational reform compounds over sixteen years

Adjacent Frameworks

• The Crisis Communications Citation Share Study
• Crisis PR pillar
• Reputation Management pillar
• Health and Wellness PR pillar
• Healthcare PR pillar
• Crisis PR Just Grew Two New Layers
• Crisis PR Is Forever Now